Back to News
Mergers & Acquisitions

‘Coronavirus Risk’ Enters M&A Lexicon

|
Published: June 22nd, 2020
Uncertainty posed by the pandemic is reshaping negotiations, upending timelines, altering strategies and killing transactions.

As the pandemic delays closings, lengthens antitrust reviews and derails mergers, dealmakers must grapple with an unforeseen variable that overhangs every transaction: coronavirus risk.

The medical crisis suddenly permeates each nuance of the investment process, from negotiation to consummation, forcing legal counsel to adjust to a new normal defined by uncertainty.

In interviews with The Deal, attorneys in New York and Washington described a merger landscape recalibrated by an unpredictable pathogen and ensuing economic volatility.

“The virus is affecting every phase of the deal process, and pretty much every page of the acquisition agreement,” said Paul Schnell, a mergers and acquisitions partner at Skadden, Arps, Slate, Meagher & Flom LLP.

“You have to think through each of these stages with a coronavirus lens,” he said.

In Washington, the Department of Justice and Federal Trade Commission have sent mixed signals. They’re operational and won’t relax standards, but they also acknowledge resources are strained due to telework.

“Most antitrust lawyers and companies who have pending transactions that have not yet been filed are cautiously proceeding, understanding that the DOJ and the FTC are going to be asking for more time and likely be slower to review,” said Neely Agin, partner at Winston & Strawn LLP.

She warned of the potential for “backlog” triggered by investments that encounter delays.

Editor’s note: The full version of this article was published earlier on The Deal’s premium subscription website. For access, log in to TheDeal.com or use the form below to request a free trial.

This Content is Only for The Deal Subscribers

The Deal provides actionable, intraday coverage of mergers, acquisitions and all other changes in corporate control to institutional investors, private equity, hedge funds and the firms that serve them.

If you’re already a subscriber, log in to view this article here.

More From Mergers & Acquisitions

Activism

The Deal Honors Top Women in Dealmaking

By The Deal Staff
|
Published: January 24th, 2021
The Deal honors exemplary women in the legal profession with a focus on M&A, private equity, restructuring and activist investing in this year's Top Women in Dealmaking list.
Mergers & Acquisitions

Drinks With The Deal: Goodwin Procter's Stuart Cable

By David Marcus
|
Published: January 7th, 2021
The vice chair and head of M&A discusses building the firm's biotech practice, helping Covid-19 vaccine developer Moderna grow over the years and recent transformational deals in the latest episode of the podcast.
Mergers & Acquisitions

Drinks With The Deal: Bryan Cave's Stephanie Hosler

By David Marcus
|
Published: December 18th, 2020
Hosler, who heads Bryan Cave Leighton Paisner's corporate and finance transactions group, talks about her experiences as a Latina M&A lawyer and her desire to help create a more diverse workplace on the latest Drinks With The Deal podcast.